Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - hydrocortisone - oral tablet - 20mg

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - hydrocortisone - oral tablet - 20mg

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - hydrocortisone - oral tablet - 20mg

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

sovereign medical ltd - hydrocortisone - oral tablet - 20mg

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

resolution chemicals ltd - hydrocortisone - oral tablet - 20mg

Estados Unidos - inglés - NLM (National Library of Medicine)

west-ward pharmaceutical corp. - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - tablet - 20 mg - - endocrine disorders   primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance)   congenital adrenal hyperplasia   nonsuppurative thyroiditis   hypercalcemia associated with cancer - rheumatic disorders   as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:   psoriatic arthritis   rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy):   ankylosing spondylitis   acute and subacute bursitis   acute nonspecific tenosynovitis   acute gouty arthritis   post-traumatic osteoarthritis   synovitis or osteoarthritis   epicondylitis - collagen diseases   during an exacerbation or as maintenance therapy in selected cases of:   systemic lupus erythematosus   acute rheumatic carditis  

Bélgica - inglés - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ace pharmaceuticals b.v. - hydrocortisone 10 mg (red tablet 10 mg); hydrocortisone 5 mg (orange tablet 5 mg) - film-coated tablet - 10 mg + 5 mg - hydrocortisone 10 mg; hydrocortisone 5 mg - hydrocortisone

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

medihealth (northern) ltd - hydrocortisone - oral tablet - 10mg

Estados Unidos - inglés - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone tablets are indicated in the following conditions. primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: - psoriatic arthritis - rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) - ankylosing spondylitis - acute and subacute bursitis - acute nonspecific tenosynovitis - acute gouty arthritis - post-traumatic osteoarthritis - synovitis of osteoarthritis - epicondylitis during an exacerbation or as maintenance therapy in selected cases of: - systemic lupus erythematosus - systemic dermatomyositis (polymyositis) - acut

Estados Unidos - inglés - NLM (National Library of Medicine)

american health packaging - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone tablets are indicated in the following conditions. - primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) - congenital adrenal hyperplasia - non suppurative thyroiditis - hypercalcemia associated with cancer as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: - psoriatic arthritis - rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) - ankylosing spondylitis - acute and subacute bursitis - acute nonspecific tenosynovitis - acute gouty arthritis - post-traumatic osteoarthritis - synovitis of osteoarthritis - epicondylitis during an exacerbation or as maintenance therapy in selected cases of: - systemic lupus erythematosus - systemic dermatomyositis (polymyositis